{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:03:53Z","timestamp":1784257433694,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00520-013-1932-2","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T05:18:12Z","timestamp":1377062292000},"page":"3497-3507","source":"Crossref","is-referenced-by-count":66,"title":["Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid"],"prefix":"10.1007","volume":"21","author":[{"given":"Roger","family":"von Moos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Egerdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danail","family":"Damyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe G.","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"key":"1932_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"1932_CR2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s\u20136249s","journal-title":"Clin Cancer Res"},{"key":"1932_CR3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00520-012-1461-4","volume":"20","author":"G Dranitsaris","year":"2012","unstructured":"Dranitsaris G, Hatzimichael E (2012) Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer 20:1353\u20131360","journal-title":"Support Care Cancer"},{"key":"1932_CR4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijrobp.2003.10.006","volume":"59","author":"YM Linden van der","year":"2004","unstructured":"van der Linden YM, Lok JJ, Steenland E, Martijn H, van Houwelingen H, Marijnen CA, Leer JW (2004) Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 59:528\u2013537","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1932_CR5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM199403033300902","volume":"330","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592\u2013596","journal-title":"N Engl J Med"},{"key":"1932_CR6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdn419","volume":"19","author":"S Deandrea","year":"2008","unstructured":"Deandrea S, Montanari M, Moja L, Apolone G (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985\u20131991","journal-title":"Ann Oncol"},{"key":"1932_CR7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0093-7754(01)90229-5","volume":"28","author":"N Janjan","year":"2001","unstructured":"Janjan N (2001) Bone metastases: approaches to management. Semin Oncol 28:28\u201334","journal-title":"Semin Oncol"},{"key":"1932_CR8","unstructured":"National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 1.2013). National Comprehensive Cancer Network"},{"key":"1932_CR9","unstructured":"National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 1.2013). National Comprehensive Cancer Network"},{"key":"1932_CR10","unstructured":"National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer (Version 2.2013). National Comprehensive Cancer Network"},{"key":"1932_CR11","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"1932_CR12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"1932_CR13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"1932_CR14","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"1932_CR15","unstructured":"(2012) Zometa\u00ae (zoledronic acid) Injection. Full prescribing information. Novartis Pharmaceuticals Corporation"},{"key":"1932_CR16","volume-title":"The brief pain inventory user guide","author":"C Cleeland","year":"2009","unstructured":"Cleeland C (2009) The brief pain inventory user guide. The University of Texas MD. Anderson Cancer Center, Houston"},{"key":"1932_CR17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-3959(96)03131-4","volume":"67","author":"CS Cleeland","year":"1996","unstructured":"Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC (1996) Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 67:267\u2013273","journal-title":"Pain"},{"key":"1932_CR18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579","journal-title":"J Clin Oncol"},{"key":"1932_CR19","unstructured":"Chung KC, Barlev A, Braun A, Qian Y, Zagari M (2009) Development of the Analgesic Quantification Algorithm (AQA): a new scale to assess analgesic use [Poster]. Joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology"},{"key":"1932_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.suponc.2010.12.004","volume":"9","author":"SD Mathias","year":"2011","unstructured":"Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K (2011) Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 9:72\u201378","journal-title":"J Support Oncol"},{"key":"1932_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","volume":"88","author":"JT Farrar","year":"2000","unstructured":"Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287\u2013294","journal-title":"Pain"},{"key":"1932_CR22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79","journal-title":"Health Qual Life Outcomes"},{"key":"1932_CR23","doi-asserted-by":"crossref","first-page":"6231s","DOI":"10.1158\/1078-0432.CCR-06-0682","volume":"12","author":"MJ Goblirsch","year":"2006","unstructured":"Goblirsch MJ, Zwolak PP, Clohisy DR (2006) Biology of bone cancer pain. Clin Cancer Res 12:6231s\u20136235s","journal-title":"Clin Cancer Res"},{"key":"1932_CR24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bone.2010.07.009","volume":"48","author":"T Yoneda","year":"2011","unstructured":"Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, Nishisho T, Sakurai T, Hiraga T (2011) Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 48:100\u2013105","journal-title":"Bone"},{"key":"1932_CR25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","volume":"6","author":"P Honore","year":"2000","unstructured":"Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521\u2013528","journal-title":"Nat Med"},{"key":"1932_CR26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bmjspcare-2011-000078","volume":"1","author":"S Kaasa","year":"2011","unstructured":"Kaasa S, Apolone G, Klepstad P, Loge JH, Hjermstad MJ, Corli O, Strasser F, Heiskanen T, Costantini M, Zagonel V, Groenvold M, Fainsinger R, Jensen MP, Farrar JT, McQuay H, Rothrock NE, Cleary J, Deguines C, Caraceni A (2011) Expert conference on cancer pain assessment and classification\u2014the need for international consensus: working proposals on international standards. BMJ Support Palliat Care 1:281\u2013287","journal-title":"BMJ Support Palliat Care"},{"key":"1932_CR27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00520-008-0487-0","volume":"16","author":"R Moos von","year":"2008","unstructured":"von Moos R, Strasser F, Gillessen S, Zaugg K (2008) Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 16:1105\u20131115","journal-title":"Support Care Cancer"},{"key":"1932_CR28","unstructured":"Milani B, Scholten W (2011) The World Medicines Situation 2011: Access to Controlled Medicines (apps.who.int\/medicinedocs\/documents\/s18062en\/s18062en.pdf). World Health Organization (WHO), Geneva"},{"key":"1932_CR29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7525-9-88","volume":"9","author":"A Gater","year":"2011","unstructured":"Gater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC (2011) Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual Life Outcomes 9:88","journal-title":"Health Qual Life Outcomes"},{"key":"1932_CR30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","volume":"28","author":"PS Brucker","year":"2005","unstructured":"Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28:192\u2013211","journal-title":"Eval Health Prof"},{"key":"1932_CR31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","volume":"15","author":"V DePuy","year":"2007","unstructured":"DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869\u2013876","journal-title":"Support Care Cancer"},{"key":"1932_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","volume":"4","author":"F Saad","year":"2005","unstructured":"Saad F (2005) Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4:31\u201337","journal-title":"Clin Prostate Cancer"},{"key":"1932_CR33","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869\u20131876","journal-title":"Br J Cancer"},{"key":"1932_CR34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","volume":"17","author":"KP Weinfurt","year":"2006","unstructured":"Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986\u2013989","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1007\/s00520-014-2293-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T00:00:00Z","timestamp":1402358400000}}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1932-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1932-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T14:47:56Z","timestamp":1563720476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1932-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1932-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00520-014-2293-1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]}}}